Document is current
Any future updates will be listed below
-
Authors
Naing, Aung https://orcid.org/0000-0002-4803-8513
Khalil, Danny
Rosen, Oliver https://orcid.org/0000-0002-4968-3143
Camidge, D Ross
Lillie, Tom
Ji, Rui-Ru
Stacey, Andrea
Thomas, Matthew https://orcid.org/0009-0005-8362-1674
Rosen, Lee
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03852511 at ClinicalTrials.govnct05165433 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
https://doi.org/10.1136/jitc-2021-003645
342 Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study
https://doi.org/10.1136/jitc-2021-sitc2021.342
Phase 1 clinical trial results for NG-350A, a novel transgene-armed and tumor-selective vector: Differential effects of intravenous (IV) versus intratumoral (IT) dosing on immune pharmacodynamics (PD).
https://doi.org/10.1200/jco.2023.41.16_suppl.2572
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
https://doi.org/10.1136/jitc-2024-010016
nct06459869 at ClinicalTrials.govDocuments that mention this clinical trial
1003 Tumor-specific replication and immunoactivity of aCD40-producing T-SIGn vectors
https://doi.org/10.1136/jitc-2024-sitc2024.1003
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
https://doi.org/10.1136/jitc-2024-010016
nct05165433 at ClinicalTrials.govDocuments that mention this clinical trial
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
https://doi.org/10.1136/jitc-2024-010016
nct06459869 at ClinicalTrials.govDocuments that mention this clinical trial
1003 Tumor-specific replication and immunoactivity of aCD40-producing T-SIGn vectors
https://doi.org/10.1136/jitc-2024-sitc2024.1003
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
https://doi.org/10.1136/jitc-2024-010016
nct03852511 at ClinicalTrials.govDocuments that mention this clinical trial
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
https://doi.org/10.1136/jitc-2024-010016
Documents that mention this clinical trial
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
https://doi.org/10.1136/jitc-2021-003645
342 Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study
https://doi.org/10.1136/jitc-2021-sitc2021.342
Phase 1 clinical trial results for NG-350A, a novel transgene-armed and tumor-selective vector: Differential effects of intravenous (IV) versus intratumoral (IT) dosing on immune pharmacodynamics (PD).
https://doi.org/10.1200/jco.2023.41.16_suppl.2572
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
https://doi.org/10.1136/jitc-2024-010016
-
Funding
Funding for this research was provided by:
Akamis Bio Ltd (N/A)
- License Information
